A universal anti-HIV-1 Tat epitope vaccine that is fully synthetic and self-adjuvanting |
| |
Authors: | Gideon Goldstein John J. Chicca II |
| |
Affiliation: | 1. Thymon L.L.C., Vaccine Development, 30 Dorison Drive, Short Hills, NJ 07078, USA;2. Molecular Diagnostic Services, Inc., 4204 Sorrento Valley Blvd., Suite G, San Diego, CA 92121, USA |
| |
Abstract: | Circulating HIV-1 Tat protein is essential for maintenance of the chronic HIV replication that predicates both HIV transmission and clinical progression to AIDS/death. A synthetic anti-Tat epitope vaccine (TUTI-16) was designed to induce neutralizing antibodies to Tat and, hopefully, provide immunological control of HIV replication. TUTI-16 is composed of (1) a conserved Tat B cell epitope (Tat 4–12), rendered universal by introducing known variant amino acids at variable positions 7, 9 and 12 during solid phase synthesis, (2) a promiscuous T helper sequence and (3) a lipopeptide toll-like receptor 2 (TLR2) agonist. TUTI-16 induced high titer antibodies against all 8 known variants of the Tat epitope. |
| |
Keywords: | HIV-1 Tat B cell vaccine Synthetic Self-adjuvanting |
本文献已被 ScienceDirect 等数据库收录! |
|